Market Signal Briefing

While 2024 was about recovery and laying foundations, 2025 will be remembered as the year BNB Chain reasserted its dominance.

Key points:

Bitcoin has been lagging gold and the S&P 500 since November, but analysts expect a rally to a new all-time high in 2026.

Several major altcoins are showing signs of starting a short-term recovery.

Bitcoin (BTC) remains stuck inside the $86,400 to $90,600 range, indicating a balance between supply and demand.

BTC has been a laggard to other asset classes, such as gold and the S&P 500, since November, but market intelligence platform Santiment said in a post on X that there is “an opportunity for crypto to play catch-up.”

Some analysts believe that BTC could benefit from increasing global liquidity in 2026. BitMEX cofounder Arthur Hayes said in a post on X that crypto could pump as dollar liquidity is moving higher after bottoming out in November.

Crypto market data daily view. Source: TradingViewAnother positive sign is that several analysts believe BTC’s four-year cycle has broken. Analyst The ₿itcoin Therapist expects BTC to hit a new all-time high as early as the first quarter of 2026. Even more bullish are the Citigroup analysts who forecast a base case BTC price target of $143,000 and a bull case of $189,000 in 2026. 

Could BTC and the major altcoins break above their overhead resistance levels? Let’s analyze the charts of the top 10 cryptocurrencies to find out.

Bitcoin price predictionBTC has been witnessing a tough battle between the bulls and the bears near the 20-day exponential moving average ($88,439).

BTC/USDT daily chart. Source: Cointelegraph/TradingViewThe tight consolidation just below the 20-day EMA increases the possibility of a break above the 50-day simple moving average ($89,880). If that happens, the BTC/USDT pair could ascend to the overhead resistance at $94,589.

This is a critical level to watch, as a break above it signals that the corrective phase may be over. The Bitcoin price could then rally to $100,000 and later to $107,500.

On the contrary, if the price turns down sharply from the moving averages, it suggests that the bears remain in command. That heightens the risk of a drop below the $84,000 support. The next stop on the downside is $80,600 and then $74,508.

Ether price predictionEther (ETH) bulls are attempting to start a relief rally by pushing the price above the 50-day SMA ($3,019).

ETH/USDT daily chart. Source: Cointelegraph/TradingViewA close above the 50-day SMA clears the path for a rally to the resistance line of the symmetrical triangle pattern. Buyers will have to propel the Ether price above the resistance line to suggest that the downtrend could be over. The ETH/USDT pair may then attempt a rally to $4,000.

On the downside, a close below the support line signals that the bears have overpowered the bulls. The pair may collapse to $2,623 and thereafter to $2,373.

BNB price predictionBuyers are attempting to drive BNB (BNB) above the 50-day SMA ($876), indicating demand at higher levels.

BNB/USDT daily chart. Source: Cointelegraph/TradingViewA close above the 50-day SMA opens the doors for a rally to the stiff overhead resistance of $928. Sellers are expected to pose a strong challenge at the $928 level, as a close above it completes a bullish ascending triangle pattern. The BNB/USDT pair may then rally toward the pattern target of $1,066.

Alternatively, if the BNB price turns down sharply from $928, it suggests that the bears are active at higher levels. The pair may then extend its stay inside the $928 to $790 range for a few more days.

XRP price predictionBuyers are attempting to start a recovery in XRP (XRP) by pushing the price above the 20-day EMA ($1.91).

XRP/USDT daily chart. Source: Cointelegraph/TradingViewIf they succeed, the XRP/USDT pair could rise to the 50-day SMA ($2.04) and, after that, to the downtrend line. Sellers are expected to fiercely defend the downtrend line, as a close above it signals a potential trend change. The pair could then rally to $2.70.

The $1.61 level is the critical support to watch on the downside. A close below the level signals the start of the next leg of the downtrend. The XRP price may then nosedive to the Oct. 10 low of $1.25.

Solana price predictionSolana (SOL) has been clinging to the 20-day EMA ($126) for the past few days, indicating that the bulls continue to exert pressure.

SOL/USDT daily chart. Source: Cointelegraph/TradingViewIf the price closes above the 20-day EMA, the SOL/USDT pair could climb to the overhead resistance at $147. There is minor resistance at the 50-day SMA ($132), but it is likely to be crossed.

Contrarily, if the Solana price turns down from the moving averages, it signals that the bears remain in control. That heightens the risk of a drop to the $108 level and eventually to the critical support at $95.

Dogecoin price predictionBuyers are struggling to push Dogecoin (DOGE) above the breakdown level of $0.13, indicating a lack of demand at higher levels.

DOGE/USDT daily chart. Source: Cointelegraph/TradingViewSellers will attempt to sink the Dogecoin price below the $0.12 level. If they can pull it off, the downtrend could resume, and the DOGE/USDT pair could descend to the Oct. 10 low of $0.10.

Buyers will have to swiftly drive the price above the moving averages to prevent the downward move. The pair could then rally to $0.19, indicating that the market has rejected the break below the $0.13 support.

Cardano price predictionCardano (ADA) turned down from the 20-day EMA ($0.37) on Monday, indicating negative sentiment.

ADA/USDT daily chart. Source: Cointelegraph/TradingViewThe bears will try to strengthen their position by pulling the price below the $0.34 level. If they succeed, the ADA/USDT pair could plummet to $0.30 and later to the Oct. 10 low of $0.27.

The first sign of strength will be a break and close above the 20-day EMA. The pair could then climb to the 50-day SMA ($0.41), where the bears are expected to mount a strong defense. If buyers overcome the barrier, the Cardano price could reach the breakdown level of $0.50.

Bitcoin Cash price predictionBitcoin Cash (BCH) is taking support at the 20-day EMA ($587), indicating that the bulls continue to buy on dips.

BCH/USDT daily chart. Source: Cointelegraph/TradingViewThat enhances the prospects of a break above the $631 level. The BCH/USDT pair could then rally to $651 and subsequently to the stiff overhead resistance at $720.

Sellers are likely to have other plans. They will strive to pull the price below the 20-day EMA. If they do that, the pair could slump to the 50-day SMA ($556). This is a crucial level for the bulls to defend, as a close below it suggests the Bitcoin Cash price may swing between $443 and $631 for some time.

Chainlink price predictionChainlink (LINK) has been trading between the 50-day SMA ($13.15) and the $11.61 support for the past few days.

LINK/USDT daily chart. Source: Cointelegraph/TradingViewThe positive divergence on the RSI suggests the selling pressure is reducing. That increases the possibility of a break above the 50-day SMA. The LINK/USDT pair may then rally to $15.01. A close above $15.01 indicates that the downtrend could be over. 

Instead, if the Chainlink price turns down sharply from the moving averages and breaks below $11.61, it signals that the bears remain in control. The pair could then plunge below the $10.94 support, opening the door for a fall to the Oct. 10 low of $7.90.

Hyperliquid price predictionSellers are defending the 20-day EMA ($26.44) in Hyperliquid (HYPE), but a positive sign is that the bulls have not ceded much ground to the bears.

HYPE/USDT daily chart. Source: Cointelegraph/TradingViewThat increases the likelihood of a break above the 20-day EMA. If that happens, the HYPE/USDT pair could climb to the 50-day SMA ($30.74) and then to the breakdown level of $35.50.

This positive view will be invalidated in the near term if the Hyperliquid price turns down from the moving averages and breaks below the $22.19 level. The pair may then retest the Oct. 10 low of $20.82.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

-

WALLA WALLA, Wash.--(BUSINESS WIRE)--Banner Corporation (NASDAQ: BANR) (“Banner”), the parent company of Banner Bank, today announced that it will report its fourth quarter results after the market closes on Wednesday, January 21, 2026. Management will host a conference call on Thursday, January 22, 2026, at 8:00 a.m. PT (11:00 a.m. ET) to discuss the results. The call will also be broadcast live via the internet.

Interested investors may listen to the call live at www.bannerbank.com. Investment professionals are invited to dial (833) 470-1428 using access code 013437 to participate in the call. A replay of the call will be available at www.bannerbank.com.

About the Company

Banner Corporation is a $16.56 billion bank holding company operating a commercial bank in four Western states through a network of branches offering a full range of deposit services and business, commercial real estate, construction, residential, agricultural and consumer loans. Visit Banner Bank on the Web at www.bannerbank.com.

Forward-Looking Statements

This press release contains statements that the Company believes are “forward-looking statements.” These statements relate to the Company’s financial condition, results of operations, plans, objectives, future performance or business. You should not place undue reliance on these statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. Factors that might cause such differences include, but are not limited to, those identified in our risk factors contained in Banner Corporation’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Such forward-looking statements speak only as of the date of this release. Banner Corporation expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in the Company’s expectations of results or any change in events.

More News From Banner Corporation

Back to Newsroom

-

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. Management will also host investor meetings during the conference.

The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace’s Investor website at https://investors.neuropace.com.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

More News From NeuroPace, Inc.

Back to Newsroom

Toronto, Ontario--(Newsfile Corp. - December 31, 2025) - SonicStrategy Inc. (CSE: SONI) (OTCQB: SONIF), a publicly traded infrastructure company focused on the Sonic blockchain, is pleased to announce that the Company has entered into an agreement with Sonic Labs to extend the previously announced convertible debenture for an additional three years.

The original convertible debenture was announced on September 11, 2025, with a six-month term scheduled to expire on March 10, 2026. In light of current market conditions, the parties have agreed to extend the debenture until March 10, 2029. The extension allows the Company to continue to maintain custody of the Sonic tokens while pursuing a NASDAQ listing, providing additional time and flexibility amid evolving digital asset market conditions.

The Company maintains custody of the 126,622,348.845 Sonic tokens received under the convertible debenture, with an approximate value of US$9.75 million, based on CoinMarketCap pricing as of December 30, 2025, the date the extension terms were negotiated.

The Amended Debenture is unsecured, non-interest bearing, and now matures on March 10, 2029, unless further extended by mutual agreement. The Amended Debenture remains convertible, into common shares at the conversion price of $4.50 USD ($6.22 CAD) per share. Conversion of the US$40 million principal amount is contingent solely upon the Company achieving a NASDAQ listing. Any common shares issued upon conversion will be subject to a three-year lock-up period. The amendment is subject to the approval of the CSE.

"These renewed terms reflect the current market conditions in the digital asset treasury market. We are confident that interest in this sector will continue to grow, and this three-year extension allows SonicStrategy to build momentum while supporting early-stage projects within the Sonic ecosystem," said Dustin Zinger, CEO of SonicStrategy.

About SonicStrategy Inc.
SonicStrategy (CSE: SONI) (OTCQB: SONIF) a public-market gateway to the Sonic blockchain ecosystem. SonicStrategy provides investors with compliant exposure to staking infrastructure and DeFi strategies across the Sonic network.

NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATION SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Note Regarding Forward-looking Statements

Certain information herein constitutes "forward-looking information" under Canadian securities laws, reflecting management's expectations regarding objectives, plans, strategies, future growth, results of operations, and business prospects of the Company. Words such as "may", "plans," "expects," "intends," "anticipates," "believes," and similar expressions identify forward-looking statements, which are qualified by the inherent risks and uncertainties surrounding future expectations.

Forward-looking statements are based on a number of estimates and assumptions that, while considered reasonable by management, are subject to business, economic, and competitive uncertainties and contingencies. The Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projected outcomes. Factors influencing these outcomes include economic conditions, regulatory developments, competition, capital availability, and business execution risks. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. In addition, staking rewards and validator earnings are subject to a variety of risks, including but not limited to changes in token price, validator performance, network participation rates, and overall blockchain activity. The value of the Company's Sonic token holdings is highly volatile, and balance sheet exposure may fluctuate materially with changes in market prices. There can be no assurance that current validator rewards or token valuations will be sustained in the future.

The forward-looking information contained in this press release represents the Company's expectations as of the date of this release and is subject to change. The Company does not undertake any obligation to update forward-looking statements, except as required by law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction. None of the Company's securities are registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.

No securities regulatory authority has either approved or disapproved the contents of this press release.

We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279258

Source: SonicStrategy Inc.

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Analyst’s Disclosure:I/we have a beneficial long position in the shares of GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Miami, FL, Dec. 31, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced plans to launch a shareholder rewards program delivering a tangible, real-world benefit through its EzFill platform.

Once launched, shareholders will receive a digital fuel-discount coupon token deposited directly into their EzFill mobile app accounts. Upon receipt, the token may be redeemed for one fueling event at a single location and can be applied across multiple vehicles or equipment, including passenger vehicles, commercial fleets, construction equipment, and marine vessels.

The coupon token will also be transferable within the EzFill app, allowing shareholders to share the benefit with friends or family while introducing new users to EzFill’s on-demand fueling services.

“This initiative will directly connect our shareholders to the real-world value of our platform,” said Michael D. Farkas, Executive Chairman and CEO of NextNRG. “It rewards our investors while expanding EzFill’s reach in the markets where they live and operate.”

NextNRG views this program as the first phase of a broader shareholder engagement strategy, with additional perks and participation opportunities to be evaluated as its energy and mobility platforms scale.

The coupon token is a service-based reward and does not represent equity, digital securities, or investment instruments. Final details regarding distribution timing, eligibility, and terms will be announced prior to launch and will comply with applicable regulatory and exchange requirements.

About NextNRG, Inc.

NextNRG Inc. (NextNRG) is Powering What's Next by integrating artificial intelligence (AI) and machine learning (ML) into utility infrastructure, battery storage, wireless EV in-motion charging, renewable energy and mobile fuel delivery, to create a unified platform for modern energy management.

At the core of its strategy is the Next Utility Operating System®, which uses AI to optimize both new and existing infrastructure across microgrids, utilities, and fleet operations. NextNRG's smart microgrids serve commercial, healthcare, educational, tribal, and government sites delivering cost savings, reliability, and decarbonization. The company also operates one of the nation's largest on-demand fueling fleets and is advancing wireless charging to support fleet electrification.

To learn more, visit www.nextnrg.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG's goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "expect," "intends," "will," and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG's business and macroeconomic and geopolitical events. These and other risks are described in NextNRG's filings with the Securities and Exchange Commission from time to time. NextNRG's forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although NextNRG's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations Contact
NextNRG, Inc.
Sharon Cohen
[email protected]

December 31, 2025 09:00 ET

 | Source:

BayFirst Financial Corp.

ST. PETERSBURG, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- BayFirst Financial Corp. (NASDAQ: BAFN) (“BayFirst” or “Company”), parent company of BayFirst National Bank (“Bank”) today announced that it will report its fourth quarter results after the market close on Thursday, January 29, 2026. Management will host a conference call on Friday, January 30, 2026, at 9:00 a.m. ET to discuss the results. The call will also be broadcast live via the internet.

Interested investors may listen to the call live under the Investor Relations tab at www.bayfirstfinancial.com. Investment professionals are invited to dial (800) 549-8228 to participate in the call using Conference ID 15602. A replay of the call will be available for one year at www.bayfirstfinancial.com.

About BayFirst Financial Corp.

BayFirst Financial Corp. is a registered bank holding company based in St. Petersburg, Florida which commenced operations on September 1, 2000. Its primary source of income is derived from its wholly owned subsidiary, BayFirst National Bank, a national banking association which commenced business operations on February 12, 1999. The Bank currently operates twelve full-service banking offices throughout the Tampa Bay-Sarasota region and offers a broad range of commercial and consumer banking services to businesses and individuals. As of September 30, 2025, BayFirst Financial Corp. had $1.35 billion in total assets.

Forward-Looking Statements

In addition to the historical information contained herein, this presentation includes "forward-looking statements" within the meaning of such term in the Private Securities Litigation Reform Act of 1995. These statements are subject to many risks and uncertainties, including, but not limited to, the effects of health crises, global military hostilities, weather events, or climate change, including their effects on the economic environment, our customers and our operations, as well as any changes to federal, state or local government laws, regulations or orders in connection with them; the ability of the Company to implement its strategy and expand its banking operations; changes in interest rates and other general economic, business and political conditions, including changes in the financial markets; changes in business plans as circumstances warrant; risks related to mergers and acquisitions; changes in benchmark interest rates used to price loans and deposits, changes in tax laws, regulations and guidance; enforcement actions initiated by our regulators and their impact on our operations; and other risks detailed from time to time in filings made by the Company with the SEC, including, but not limited to those “Risk Factors” described in our most recent Form 10-K and Form 10-Q. Readers should note that the forward-looking statements included herein are not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking statements.

Contacts: Thomas G. ZernickScott J. McKimChief Executive OfficerChief Financial Officer727.399.5680727.521.7085  

Key Takeaways LME copper hit a record above $12,000 per ton this year, up 42% YTD, as demand collides with fragile supply.AI data centers create inelastic copper demand; Wood Mackenzie sees 24% global demand growth by 2035.Diversified copper ETFs drew interest, with COPX up 95.3% YTD as investors target a 2026 setup.
Copper prices have surged to historic highs this year, with London Metal Exchange (“LME”) copper recently topping $12,000 per metric ton, reflecting a 42% year-to-date increase. This remarkable rise is driven by a structural market shift — explosive demand from artificial intelligence (AI) is colliding with constrained global supply, creating what analysts describe as a “very tight” market.

Indeed, while factors like U.S. tariffs, weak dollar, and inventory stockpiling triggered the initial price rally, the underlying fundamentals, particularly that of surging demand tied to electrification and digital infrastructure, suggest we are entering a long-term "supercycle." 

For investors, this backdrop presents an opportune moment to make a grand entry into diversified copper exchange-traded funds (ETFs), rather than making concentrated bets on individual miners, as a profitable move for 2026.

Before suggesting a few copper ETFs to consider for your watchlist, it’s worth exploring the strong link between AI and copper demand, other key growth catalysts for the red metal, and its overall growth prospects. Understanding these factors can help investors make more informed decisions.

AI Boom and Copper DemandThe rapid build-out of AI data centers has lately emerged as a major new pillar of copper demand, thanks to the metal’s critical role in high capacity power lines, transformers and cooling infrastructure. 

To this end, industry experts like Wood Mackenzie highlight that data center demand is highly "inelastic," meaning developers will pay whatever it costs to secure copper, which represents a tiny fraction of total project budgets. According to Wood Mackenzie’s Horizons report, published in October 2025, global copper demand is estimated to surge 24% by 2035, with AI playing a critical role as a growth catalyst. 

Notably, Wood Mackenzie believes a sudden surge in data center construction can trigger price spikes of 15% or more for the red metal. With AI projected to consume an additional 2,200 TWh of electricity by 2035 (as per global data centre projects tracked by Wood Mackenzie's Power team), we may expect to witness more copper price inflation in the coming days.

AI Apart Demand Picture: 2026 & BeyondAI is just one driver of the broader surge in copper demand, alongside the energy transition, grid modernization, and transport electrification. Beyond data centers, initiatives focused on national security and infrastructure resilience are also reshaping global copper demand.

Meeting this enormous demand will require around 8 million tons of new mine capacity plus 3.5 million tons of additional scrap (as per Wood Mackenzie). Surely, this creates a golden opportunity for a steady price hike amid an already scarce supply of the red metal, with major disruptions at mines like Grasberg in Indonesia and falling ore grades in Chile having led to a projected 330,000-ton deficit for 2026 (as estimated by JP Morgan). 

Copper price prospects remain strong over the coming years, though 2026 forecasts vary. J.P. Morgan is particularly optimistic, projecting LME copper to average $12,500 per ton in second-quarter 2026 and $12,075 for the full year, citing supply disruptions and the AI-driven demand surge as key upside factors.

On the other hand, Goldman Sachs expects a near-term pullback from record highs to an average of $10,710 in the first half of 2026, while for the full year, it forecasts prices to remain in the range of $10,000-$11,000, with the expectation that the global surplus of supply will prevent copper prices from exceeding $11,000. However, by 2035, Goldman Sachs predicts the LME copper price to reach a solid $15,000 per ton.

Copper ETFs to ConsiderGiven the strong convergence of demand drivers and supportive institutional forecasts, investors looking to gain exposure may consider the following copper ETFs:

Global X Copper Miners ETF (COPX - Free Report)

This fund, with assets worth $4.56 billion, provides exposure to 41 copper mining companies. COPX has surged a solid 95.3% year to date. Its net asset value (NAV) was $72.20 as of Dec. 30, 2025.

The fund charges 65 basis points (bps) as fees. It traded at a good volume of 3.77 million shares in the last trading session. 

iShares Copper and Metals Mining ETF (ICOP - Free Report)

This fund, with net assets worth $171 million, provides exposure to 48 global copper and metal ore miners. ICOP has soared 79.8% year to date. Its top three holdings include Freeport McMoran (FCX - Free Report) (8.18%), Anglo American NGLOY (7.91%), and BHP Group (BHP - Free Report) (7.73%).

Its NAV was $44.42 as of Dec. 30, 2025. The fund charges 47 bps as fees. It traded at a volume of 0.18 million shares in the last trading session. 

Sprott Copper Miners ETF (COPP - Free Report)

This fund, with net assets worth $97.4 million, provides exposure to physical copper and 62 copper miners. COPP has rallied 71.7% year to date. 
Its NAV was $34.93 as of Dec. 30, 2025. The fund charges 65 bps as fees. It traded at a volume of 0.18 million shares in the last trading session.

United States Copper ETF (CPER - Free Report)

This fund, with net assets worth $460.7 million, reflects the performance of the investment returns from a portfolio of copper futures contracts on the COMEX exchange. CPER has gained 40.1% year to date.

Its NAV was $35.44 as of Dec. 30, 2025. The fund charges 106 bps as fees. It traded at a volume of 1.39 million shares in the last trading session. 

$1.5 billion transaction to expand fiber deployments, launch network modernization initiatives, and accelerate growth 

, /PRNewswire/ -- DigitalBridge Group, Inc. ("DigitalBridge" or the "Company") (NYSE: DBRG), a leading global alternative asset manager dedicated to investing in digital infrastructure, and Crestview Partners ("Crestview"), a leading private equity firm, today announced that affiliated investment funds have completed their previously announced take-private acquisition of WideOpenWest, Inc. ("WOW!"), a top provider of fiber-broadband internet services and advanced connectivity solutions in the United States.

"We are excited to complete this transaction and begin a new era of growth. We look forward to investing in network and customer experience enhancements, pursuing operational excellence, and delivering an exceptional connected experience over WOW!'s high-performance networks," said Jonathan Friesel, Senior Managing Director and Head of Fiber at DigitalBridge.

Brian Cassidy, President and Head of Media at Crestview Partners, said, "As a private company, WOW! will have strategic flexibility and resources to compete more effectively in its markets and pursue long-term growth. We believe this strategic infrastructure investment will allow us to bring advanced technology to these markets more quickly and will strengthen WOW!'s competitive position."

WOW! shareholders will receive $5.20 in cash per WOW! share in a transaction with an enterprise value of approximately $1.5 billion. With the completion of the transaction, WOW! common stock is no longer traded or listed on any public securities exchange.

Advisors
Centerview Partners LLC acted as the sole financial advisor to the special committee of the WOW! Board of Directors formed to lead the evaluation of the potential transaction, and Wachtell, Lipton, Rosen & Katz acted as its legal counsel.

LionTree Advisors acted as sole financial advisor to DigitalBridge and Crestview. Morgan Stanley and Goldman Sachs served as structuring advisors to the transaction.

Simpson Thacher & Bartlett LLP acted as legal counsel to DigitalBridge, and Davis Polk & Wardwell LLP acted as legal counsel to Crestview.

About DigitalBridge

DigitalBridge (NYSE: DBRG) is a leading global alternative asset manager dedicated to investing in digital infrastructure. With a heritage of 30 years investing in and operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, the DigitalBridge team manages $108 billion of infrastructure assets on behalf of its limited partners and shareholders. For more information, visit: www.digitalbridge.com.

About Crestview

Founded in 2004, Crestview is a New York-based private equity firm focused on the middle market. The firm manages funds with over $10 billion of aggregate capital commitments and is led by a group of partners who have complementary experience and backgrounds in private equity, finance, operations and management. Crestview has senior investment professionals focused on sourcing and managing investments in each of the firm's specialty areas: media, industrials, and financial services. For more information, please visit www.crestview.com.

About WOW! 

WOW! is one of the nation's leading broadband providers delivering high-speed Internet services, cable TV, home phone, mobile phone, business data, voice, and cloud services to homes and businesses in 20 markets, including in Michigan, Alabama, Tennessee, South Carolina, Georgia and Florida. For more information, visit wowway.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release that are not historical facts contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to the acquisition of WOW! by funds affiliated with DigitalBridge Investments and Crestview Partners (the "Transaction"), including financial estimates and statements as to the effects of the Transaction.  These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events. Forward-looking statements include all statements that are not historical fact and can be identified by terms such as "may," "intend," "might," "will," "should," "could," "would," "anticipate," "expect," "believe," "estimate," "plan," "project," "predict," "potential," "continue," "likely," "target" or similar expressions or the negative of these terms  or other comparable terminology that convey uncertainty of future events or outcomes. By their nature, forward-looking statements address matters that involve risks and uncertainties because they relate to events and depend upon future circumstances that may or may not occur. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) potential litigation relating to the Transaction that could be instituted against DigitalBridge, Crestview, WOW! or their respective affiliates, directors, managers or officers, including the effects of any outcomes related thereto; (ii) the risk that disruptions from the Transaction, including the diversion of management's attention from WOW!'s ongoing business operations, will harm WOW!'s business, including current plans and operations; (iii) the ability of WOW! to retain and hire key personnel in light of the Transaction; (iv) potential adverse reactions or changes to business relationships resulting from the  completion of the Transaction; and (v) the risks and uncertainties pertaining to WOW!'s business, including those set forth in Part I, Item 1A of WOW!'s most recent Annual Report on Form 10-K, Part II, Item 1A of WOW!'s subsequent Quarterly Reports on Form 10-Q, and other filings made by WOW! with the U.S. Securities and Exchange Commission. The foregoing list of important factors is not exhaustive. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on WOW!'s financial condition, results of operations, credit rating or liquidity. In light of the significant uncertainties in these forward-looking statements, WOW! cannot assure you that the forward-looking statements in this communication will prove to be accurate, and you should not regard these statements as a representation or warranty by WOW!, its directors, officers or employees or any other person that WOW! will achieve its objectives and plans in any specified time frame, or at all. These forward-looking statements speak only as of the date they are made, and WOW! does not undertake to and specifically disclaims any obligation to publicly release the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required by applicable law.

Media Contacts

DigitalBridge
Jonathan Keehner/Sarah Salky
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
[email protected]

Crestview
Jeffrey Taufield or Daniel Yunger
Kekst CNC
(212) 521-4800
[email protected] or [email protected]

WideOpenWest, Inc. 
Debra Havins
Vice President, Corporate Communications
(720) 527-8214
[email protected]

SOURCE DigitalBridge; Crestview Partners; WideOpenWest (WOW!)

Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The Company had previously announced that it was notified by Nasdaq on December 4, 2025, that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s common shares had been below $1.00 for more than 30 consecutive business days.

On December 30, 2025, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from December 15 through December 29, 2025, the closing bid price of the Company’s common shares was $1.00 per share or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
[email protected]

Telephone: (604) 260-1566
US: [email protected]

General Inquiries
[email protected]
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing innovative treatments for AUD, the high level of interest from both patients and leading clinical sites in CMND-100, CMND-100’s potential to transform AUD treatment and its belief that that this rapid progress positions it to generate additional valuable data, bringing it closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

HomeETFs and Funds AnalysisETF Analysis

SummaryIn my equity watchlist there will not be only the USA, I will closely follow global markets, especially factor strategies.In the bond segment, I really appreciate active management; I think passive ones will remain poorly able to capture the evolutions of 2026.Among the segments with alpha potential, I identify the small cap value segment due to lower valuations and better earnings expectations.As interesting hedgers, I look with interest at CTA trend following solutions.Below is my ETF Watchlist. Alistair Berg/DigitalVision via Getty Images

In 2025, you faced Liberation Day, recession fears, the war in Ukraine, the war in the Middle East, the trade war and a shutdown, yet it was once again a year of strong performance for global markets. As relative equity valuations

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The author expresses only personal opinions and does not provide financial advice. The content is for informational purposes only and should not be considered as investment recommendations. The author assumes no responsibility for any investment decisions made based on this article. Always conduct your own research or consult with a financial advisor before making any investment choices. The author makes no guarantees regarding the data, and the user agrees that the author shall not be held liable for the user's use of the data.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of APA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

About Emily Jarvie
Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more

About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.

Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.

The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.

Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.

Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.

Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.

While the FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the company’s GRADIENT trial provided confirmatory evidence, the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.

“We are surprised and disappointed by this outcome,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Our commitment to patients suffering from the effects of hypercortisolism is unwavering. I am confident we will find a way to get relacorilant to the patients it could help. We will meet with the FDA as soon as possible to discuss the best path forward.”

About Relacorilant

Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not to the body's other hormone receptors. Corcept is developing relacorilant in endogenous hypercortisolism and a variety of other serious disorders, including ovarian cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the FDA and the European Commission (EC) for the treatment of hypercortisolism and by the EC for the treatment of ovarian cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. Corcept also recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC’s website.

In this press release, forward-looking statements include statements concerning: the clinical data concerning the safety and efficacy of relacorilant, including the results of our GRACE and GRADIENT trials; our plans to meet with the FDA as soon as possible; and any new clinical data, analyses or regulatory processes that may be required for relacorilant to receive approval as a treatment for patients with endogenous hypercortisolism or any other indication. We disclaim any intention or duty to update forward-looking statements made in this press release.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kody's Dividends, Justin Law, and Rachel Kaufman are part of the Dividend Kings team

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its non-brokered private placement (the "Private Placement") flow-through units (the " FT Units") as previously announced in the Company's news release dated December 17, 2025.

The Second Tranche consisted of the issuance of 80,000 Flow Through Units at a price of $1.30 per Unit for aggregate gross proceeds of $104,000. Each FT Unit shall consist of one common share of the Corporation (a "FT Share") and one common share purchase warrant (each, a "Warrant") (each of which qualifies as a "flow-through share" within the meaning of subsection 66(15) the Income Tax Act (Canada) (the "ITA"). Each Warrant entitles the holder thereof to purchase one common share of the Corporation (a "Warrant Share") (on a non-"flow-through" basis) at an exercise price of $2.00 per Warrant Share for a period of 24 months following the Closing Date being May 2, 2026.

Combined with Tranche 1, which closed on December 22, 2025, the Company has raised gross proceeds of $829,099.70 and has paid a total of $27,502.50 in Cash finders fees and a total of 1,925 in finders warrants to certain Qualified finders for the placement,

Proceeds from the Second Tranche will be used to fund the current exploration program on the Company's BC projects, particularly for the polymetallic Hat Project located in northwestern BC, and for general working capital. In connection with the closing of the second tranche the Company will pay finders fees in Cash of $25,000 to PB Markets Inc.

All securities issued pursuant to the Second Tranche are subject to a four-month-and-one-day hold period expiring May 2, 2026, in accordance with applicable securities laws.

The Private Placement is subject to the final approval of the TSX Venture Exchange. The Company anticipates closing the remaining portion of the Private Placement in the coming weeks.

About Doubleview Gold Corp

A mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange (TSXV: DBG), (OTCQB: DBLVF), (WKN: A1W038), and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.

Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279274

Source: Doubleview Gold Corp.

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

VANCOUVER, BC, December 31st. 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating initiatives over the past year following the integration of the DPX™ platform into the BioVaxys business.   The Company's focus continues to drive organic growth by:

TORONTO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- CHAR Technologies Ltd. (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to provide a year-end corporate update highlighting progress across its development portfolio and key priorities as the Company enters 2026. In December 2025, the Company also listed on the Frankfurt Stock Exchange (ticker 68K).

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY): (i) securities between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period"); and/or (ii) common stock pursuant and/or traceable to Firefly Aerospace's offering documents issued in connection with Firefly Aerospace's August 7, 2025 initial public offering (the "IPO"), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Firefly Aerospace class action lawsuit.  Captioned Diamond v. Firefly Aerospace Inc., No. 25-cv-01812 (W.D. Tex.), the Firefly Aerospace class action lawsuit charges Firefly Aerospace as well as certain of Firefly Aerospace's top executives and directors with violations of the Securities Act of 1933 and/or the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Firefly Aerospace class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-firefly-aerospace-inc-class-action-lawsuit-fly.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Firefly Aerospace operates as a space and defense technology company and provides mission solutions for national security, government, and commercial customers.  According to the Firefly Aerospace class action lawsuit, on or about August 7, 2025, Firefly Aerospace conducted its IPO, issuing approximately 19.3 million shares of common stock to the public at the offering price of $45.00 per share.

The Firefly Aerospace class action lawsuit alleges that defendants throughout the Class Period and in the IPO's offering documents made false and/or misleading statements and/or failed to disclose that: (i) Firefly Aerospace had overstated the demand and growth prospects for its Spacecraft Solutions offerings; (ii) Firefly Aerospace had overstated the operational readiness and commercial viability of its Alpha rocket program; and (iii) the foregoing, once revealed, would likely have a material negative impact on Firefly Aerospace.

The Firefly Aerospace investor class action alleges that on September 22, 2025 Firefly Aerospace reported its first earnings report as a public company and, among other items, revealed a loss of $80.3 million for the second quarter of 2025 compared to $58.7 million for the same quarter in 2024.  Firefly Aerospace also reported revenue of $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter in 2024, the complaint alleges.  Significantly, Firefly Aerospace reported revenue of only $9.2 million in its Spacecraft Solutions business segment, representing a 49% year-over-year decrease, the Firefly Aerospace shareholder class action alleges.  On this news, the price of Firefly Aerospace's shares fell more than 15%, the lawsuit alleges.

Then, the Firefly Aerospace class action alleges that on September 29, 2025, Firefly Aerospace disclosed that "the first stage of Firefly's Alpha Flight 7 rocket experienced an event that resulted in a loss of the stage."  On this news, the price of Firefly Aerospace's shares fell more than 20%, the complaint alleges.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Firefly Aerospace securities during the Class Period and/or common stock pursuant and/or traceable to the IPO to seek appointment as lead plaintiff in the Firefly Aerospace class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Firefly Aerospace investor class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Firefly Aerospace shareholder class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Firefly Aerospace class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

            Robbins Geller Rudman & Dowd LLP

            J.C. Sanchez, Jennifer N. Caringal

            655 W. Broadway, Suite 1900, San Diego, CA 92101

            800-449-4900

            [email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.

Dear Shareholders,

As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of Chief Executive Officer. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel dual inhibitor of PARP and the WNT pathway- for advanced ovarian cancers as well as other advanced, difficult-to-treat cancers such as recurrent Small Cell Lung Cancer. The progress we have made has been remarkable- we have strengthened our financial future while simultaneously accelerating stenoparib toward FDA approval. In the season of reflection, I wanted to take a few moments to review these past two years and build on that momentum for 2026 and beyond.

2024 – A Strategic Reset and Foundation for Progress
Looking back, the first full calendar year of my tenure, 2024, was a year of strategic reset for Allarity. We undertook a comprehensive realignment, shedding legacy programs that had limited value in order to focus exclusively on stenoparib and its incredible potential as a game changing therapy for advanced ovarian and other cancers. That focused approach has allowed us to realize and now deepen our understanding of stenoparib’s unique therapeutic mechanism of action, to separate this molecule from the first-generation PARP inhibitors. It has also allowed us to expand the possibilities for stenoparib beyond ovarian cancer. Solidifying this unique mechanism, deepening our clinical experience showing durable clinical benefit with a uniquely attractive safety profile has opened up the future for this molecule and for the enterprise value creation it affords Allarity as a company. That we have now placed stenoparib squarely on a path toward clinical and regulatory success is highlighted by the FDA’s recent decision to grant stenoparib Fast Track Designation.

At the same time, we took critical steps to strengthen the company’s corporate and financial foundations. Our capital structure was simplified, resulting in a single class of common stock, and the company regained full compliance with Nasdaq listing standards. These developments ensured continued access to the public markets and removed longstanding structural overhangs that had weighed on the investment case for our company. Equally important, we resolved outstanding legacy matters with the SEC inherited from the Company’s prior period, allowing us to move forward with a full focus on execution and long-term value creation.

Operationally, we streamlined the organization, recruited experienced oncology leadership, and implemented cost-efficiency measures designed to extend our financial runway without compromising clinical development priorities. As a result, we ended 2024 as a more focused organization, supported by a strengthened balance sheet and a clear strategic direction.

2025 – Executing with Focus and Expanding Potential
In 2025, we remained focused on accelerating stenoparib toward FDA approval in ovarian cancer. Importantly, we have now also extended stenoparib’s clinical potential to additional high value cancer indications, most notably recurrent Small Cell Lung Cancer- a devastating disease without clear therapeutic options. All of this was accomplished while further strengthening our company’s financial health.

Our confidence in stenoparib was further reinforced by the continued clinical benefit evident from our first trial dosing patients twice daily. Specifically, we presented updated data at the AACR Special Conference on Ovarian Cancer showing median Overall Survival had not been reached even though the median time to follow up exceeded 22 months. For context, the most exciting recent advances approved or submitted for the treatment of advanced ovarian cancer patients have shown median overall survival of approximately 16 months. Notably, two patients have now remained on therapy for over 30 months—a rare outcome for such advanced patients- underscoring both the durability of clinical benefit and the favorable safety profile of stenoparib. These data continue to support our belief that stenoparib’s unique, dual inhibition of PARP and WNT pathways offers distinct, practical advantages compared to first-generation PARP inhibitors. Indeed, we have now begun a new Phase 2 trial protocol to confirm and extend these results and to accelerate stenoparib toward FDA approval. We have also begun to explore clinical opportunities for stenoparib beyond ovarian cancer, signing an agreement to explore stenoparib in a recurrent small cell lung cancer trial fully funded by the US Veteran’s administration. This is the first trial to explore the activity of stenoparib in combination with other cancer agents and ideally allows us to show that stenoparib can be the combination therapy of choice for numerous cancer indications. Moreover, we have been collaborating with the Indiana Biosciences Research Institute (IBRI) to more fully appreciate stenoparib’s role in blocking the WNT pathway- a key pathway activated in many advanced cancer, most notably colorectal cancers. These preclinical studies will provide the foundation for further expanding the enterprise value of stenoparib.

We also advanced our DRP® companion diagnostic platform, entering into a new licensing and laboratory services agreement that validated the platform’s utility beyond our internal pipeline. These activities reinforce the value of our proprietary tools while offsetting costs and supporting broader industry adoption.

Financially, we maintained a disciplined operating model. Our cash runway remains aligned with our development objectives, and we continue to manage operating expenses and liabilities with rigor. During the year, we made selective and tactical use of our share repurchase capacity as part of our broader approach to shareholder stewardship, while preserving financial stability.

Taken together, the progress made in 2025 reflects an organization executing with focus and intent. We advanced stenoparib toward FDA approval in ovarian cancer, broadened its potential into new indications, and further reinforced the scientific and financial foundations that will support continued clinical development. This combination of clinical momentum and financial discipline positions Allarity well for the next stage of progress.

2026 – From Foundation to Continued Progress
Looking ahead, 2026 represents an inflection point for Allarity. Our focus is on expanding the enterprise value of Allarity—by first looking to deepen and accelerate the advanced of stenoparib toward approval, by expanding the indications for stenoparib and by being opportunistic in finding additional avenues to enhance and expand the Allarity enterprise.

In Closing
The past two years have required decisive change, hard choices, and persistent focus. The decisions we have made throughout the last two years have positioned Allarity to continue to move forward as a more capable and credible company, focused on bringing better cancer therapies to patients. As we enter 2026, I am confident that the foundation we have laid will support meaningful progress across clinical, regulatory, and strategic dimensions. Thank you for your continued belief in our mission and for joining us on this journey.

Sincerely,
Thomas H. Jensen
Chief Executive Officer

About Stenoparib/2X-121
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still receiving benefit from stenoparib administration. The updated data from this study were presented at this AACR special conference on advances in Ovarian Cancer. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients began enrolling patients this summer. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval.

About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.

About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company’s strategy, plans, and objectives; the clinical development, potential regulatory approval, and commercial prospects of stenoparib; expectations regarding ongoing and future clinical trials, including enrollment, data generation, and study outcomes; potential expansion of stenoparib into additional cancer indications; anticipated regulatory interactions; the development and potential commercialization of stenoparib; the utility and adoption of the Company’s DRP® companion diagnostic platform; and the Company’s ability to maintain financial discipline, preserve financial stability, and pursue strategic or development opportunities. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risksrisks related to the Company’s ability to successfully advance the clinical development of stenoparib; uncertainties inherent in clinical trials, including patient enrollment, timing, data interpretation, and outcomes; the timing and outcome of regulatory interactions and approval processes; the potential for delays or changes in development plans; reliance on third parties for clinical, manufacturing, or research activities; competition from other therapies; manufacturing, supply chain, and scale-up risks; the Company’s ability to maintain financial discipline and obtain additional financing if needed; and general market, economic, and industry conditions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and our Form 10-Q quarterly reports filed with the SEC on May 9, 2025, August 15, 2025 and November 14, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:         
        [email protected]

        
Media Contact:
        Thomas Pedersen
        Carrotize PR & Communications
        +45 6062 9390
        [email protected]

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

December 31, 2025 08:00 ET

 | Source:

Sonoro Gold Corp.

VANCOUVER, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it has closed its previously announced oversubscribed, non-brokered private placement of 24,500,000 units (the “Units”) at $0.20 per unit, for gross proceeds of CAD $4,900,000.  Each Unit consists of one Sonoro common share and one common share purchase warrant.  Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of three years from the closing of the private placement at an exercise price of CAD $0.28 per share.

No finder fees were paid in connection with the Offering.

All securities issued and issuable in connection with the Offering are subject to a 4-month plus one day hold period ending May 1, 2026. The Offering has received conditional acceptance from the TSX Venture Exchange but remains subject to receipt of final acceptance from the TSX Venture Exchange. 

Insiders of the Company participated in the Offering by subscribing for 2,215,000 Units for gross proceeds of $443,000, constituting a related party transaction pursuant to TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101, as the fair market value of the transaction did not exceed 25% of the Company’s market capitalization.

The net proceeds from the Offering will be used to fund the ongoing development of the Company’s Cerro Caliche gold project in Sonora, Mexico and for general working capital purposes. The project is in the final permitting stage for a proposed open-pit, heap leach mining operation.

About Sonoro Gold Corp.
Sonoro Gold Corp. is a publicly listed exploration and development Company holding the development-stage Cerro Caliche project and the exploration-stage San Marcial project in Sonora State, Mexico.  The Company has highly experienced operational and management teams with proven track records for the discovery and development of natural resource deposits.

To keep up-to-date on Sonoro’s developments, please join our online communities on X, Facebook, LinkedIn, Instagram and YouTube , and visit Sonoro’s website and subscribe to receive the latest news and updates delivered straight to your inbox.

On behalf of the Board of SONORO GOLD CORP.
Per:    “Kenneth MacLeod”
            Kenneth MacLeod
            President & CEO
For further information, please contact:
Sonoro Gold Corp. - Tel: (604) 632-1764
Email: [email protected]

Forward-Looking Statement Cautions:
This press release may contain "forward-looking information" as defined in applicable Canadian securities legislation. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Cerro Caliche project, and future plans and objectives of the Company, constitute forward looking information that involve various risks and uncertainties, including statements regarding project permitting and the Company’s intention to develop and operate the proposed Cerro Caliche gold mine. Although the Company believes that such statements are reasonable based on current circumstances, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective" and similar expressions, or that events or conditions "will", "would", "may", "can”, "could" or "should" occur, or are those statements, which, by their nature, refer to future events.  The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties, including the possibility of unfavorable exploration and test results, the lack of sufficient future financing to carry out exploration and development plans and unanticipated changes in the legal, regulatory and permitting requirements for the Company’s exploration programs.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or the policies of the TSX Venture Exchange. Readers are encouraged to review the Company’s complete public disclosure record on SEDAR at www.sedar.com.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act (“Regulation S”), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act”

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release

HomeStock IdeasQuick Picks & Lists

SummaryComstock Resources (CRK) transformed after Jerry Jones invested $1 billion, shifting focus to the Haynesville Basin.Initial concerns about Haynesville's high-cost, swing-basin nature were mitigated by the Western Haynesville discovery.Enterprise Products Partners is likely the safest of the group but issues a K-1.Industry conditions remain fast-moving, requiring ongoing reassessment of favorite stock positions.Crescent Energy may take the longest period of time to determine success or failure.This idea was discussed in more depth with members of my private investing community, Oil & Gas Value Research. Learn More » Funtay/iStock via Getty Images

Every now and then I get to think about my favorite stocks. But this is a very fast-moving area where favorites can quickly change with fast-moving industry conditions. Given that caveat, before we get started, here are my current

Analyst’s Disclosure:I/we have a beneficial long position in the shares of XOM CRK EPD PEYUF CRGY CVX AR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor, and this article is not meant to be a recommendation of the purchase or sale of stock. Investors are advised to review all company documents and press releases to see if the company fits their own investment qualifications.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

For investors seeking momentum, SPDR EURO STOXX 50 ETF (FEZ - Free Report)  is probably on radar. The fund just hit a 52-week high, and is up 36.6% from its 52-week low of $47.63 per share.

But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:

FEZ In FocusThe underlying EURO STOXX 50 Index is designed to represent the performance of some of the largest companies across components of the 19 EURO STOXX Supersector Indexes. The fund charges 29 bps in fees.

Why The Move?Europe investing has outperformed the United States in 2025. The FEZ is up 35.8% so far this year, outperforming key U.S. equity gauges. Cheaper valuation, upbeat corporate earnings and lower interest rates in Europe have led to the rally.

More Gains Ahead?Though FEZ has a Zacks ETF Rank #3 (Hold) currently, it might continue its strong performance in the near term, given a positive weighted alpha of 31.11.

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' hormone-blocking drug for the treatment of a rare hormonal disorder, the company said on Wednesday.